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ABSTRACT 
The Amyotrophic Lateral Sclerosis (ALS) and the Spinal Muscular Atrophy 
(SMA) are neurodegenerative disorders characterized by progressive loss of motor 
neurons.  
The SMA is generally caused by homozygous deletion or mutation of the SMN 
gene (1) (2) (3); which encodes for a protein that is ubiquitous and multifunctional and it 
is highly expressed in the spinal cord (4). 
The ALS is a familial or a sporadic disease. The 20% of the cases of the familial 
ALS is caused by a dominant mutation in the SOD1 gene (5) (6). In addition FUS and 
TARDBP are two other genes involved in this disease (7). 
The purpose of my thesis is to study the gene, the isoforms, the subcellular 
localization and the molecular partners of SMN protein.  
We studied the SMN gene by RFLP-PCR and we discovered that there is not 
deletion in exon 7 and in exon 8 of this gene.  
Therefore, SMN is not implicated in the pathogenesis of ALS at genetic level; 
for this reason we analyzed the SMN protein. We chose also two other proteins, FUS 
and TDP-43 because they have the prerequisites for interacting with SMN protein. In 
fact they have a rich in glycine domain and this is fundamental for the interaction with 
the SMN protein (8). Our studies revealed that the proteins analyzed have different 
isoforms. 
In addition we found that SMN and TDP-43 proteins are both in the nucleus and 
in the cytoplasm, conversely the FUS protein is only in the nucleus. 
We subsequently evaluated the interaction of the SMN with the FUS protein by 
co-immunoprecipitation. It showed that only a specific isoform of FUS interacts with 
the SMN protein and this interaction occurs only in the nucleus. 
Then we understood that the localization of the FUS and the SMN proteins and 
their interaction does not change during differentiation of neuroblastoma cells (SH-
6 
 
SY5Y) into neuronal-like adult cells by retinoic acid treatment and pretreatment with 
poly-lysine/poly-ornithine. 
Conversely, the localization of the FUS protein changes in human fibroblasts, 
taken from skin biopsy of an asymptomatic subject with P525L FUS mutation. In these 
cells the FUS protein is found both in the nucleus and in the cytoplasm. 
The translocation of the mutated FUS from the nucleus to the cytoplasm has 
already been discovered by other authors in patients with amyotrophic lateral sclerosis. 
Here we show, for the first time, that the same phenomenon is present in a subject with 
FUS mutation but asymptomatic. 
In conclusion, from all these analyzes, it is possible to deduce that: 
 The SMN gene deletion is not present in ALS patients. 
 SMN and FUS proteins interact in the nucleus of neuroblastoma cells 
(SH-SY5Y). 
 SMN and FUS proteins maintain the same location in the different cells 
types analyzed. 
  The FUS protein moves itself to the cytoplasm in an asymptomatic 
subject with P525L mutation in the FUS gene. 
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INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS).  
The amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative 
disorder characterized by progressive loss of the upper motor neurons and lower motor 
neurons (figure 1) (1) (2). 
 
Figure 1: Representation of upper and lower motor neuron. 
ALS ‘s pathogenic mechanism is unknown but many factors have been 
considered, including gene’s mutations, mitochondrial damage, oxidative stress, 
glutamate excitotoxicity, viral infection, protein aggregation, environmental factors. In 
addition microglia and astrocytes seem to be involved (9). 
The major environmental causes of this disease are: cigarette smoking (10) (11), 
exposure to heavy metals (12), pesticides (13) and intensive physical activity (14). 
In 95% of cases ALS is sporadic (s-ALS) and it is only in 5% of the cases 
genetically transmitted (f-ALS) (15).  
f-ALS can be transmitted in autosomal dominant manner (in which the majority 
of affected individuals has a sick parent), autosomal recessive manner (rare, the parents 
of an affected individual are obligate heterozygotes but healthy) or X-linked (rare) (16). 
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Specifically, the 20% of cases of f-ALS is caused by a dominant mutation in the 
SOD1 gene (5) (6), though many genes appear to be involved in the ALS pathogenesis, 
for example chromosome 9 open reading frame 72 (C9orf72), superoxide dismutase-1 
(SOD1), angiogenin (ANG), fused in sarcoma/translated in liposarcoma (FUS/TLS), 
TAR DNAbinding protein 43 (TARDBP/TDP-43), vesicle-associated membrane protein 
B (VAPB), optineurin (OPTN), valosin-containing protein (VCP), ubiquilin-2 
(UBQLN2), sequestosome-1 (SQSTM1), and profilin-1 (PFN1) (17). 
In addition, some of these genes are involved in the RNA metabolism (18). 
However, an unsolved enigma is how the disruption of ubiquitously expressed splicing 
factors can cause selective dysfunction of specific neurons (19). 
To solve this question various assumptions have been proposed, including the 
presence of neuro-specific factors, like n-PTB (polypirimidine binding protein or 
hnRNP I) (21) (22) and NOVA (Neuro-Oncological Ventral Antigen) (22) or the presence 
of mutations in splicing sites of neuro-specific proteins. For example, it was discovered 
that the amino acid transporter EAAT2 gene, which protects neurons from glutamate 
excitotoxicity, is mutated in some cases of ALS, this mutation is in splicing sites and it 
causes loss of the protein and then cell damage (23).  
Spinal Muscular Atrophy (SMA) and Survival  Motor Neuron 
(SMN) gene. 
The Spinal Muscular Atrophy is a recessive genetic disease with early onset, 
which affects lower motor neurons and it causes skeletal muscle atrophy. There are 
different types of SMA based on the onset age and the disease severity (24). 
In particular, SMA is caused by homozygous deletion in SMN1 gene (3) (25).  
The SMN gene is 27 kb and includes 9 exons (exons 1, 2a, 2b, and 3–8) (27). 
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Figure 2: Diagram showing the SMN locus. http://ghr.nlm.nih.gov/gene/SMN1. 
In humans, this gene is on chromosome 5q13 (figure 2) and it is present in two 
copies: SMN1 (telomeric copy) and SMN2 (centromeric copy) (3) (26), that have identical 
sequence, except 5 nucleotides (one in intron 6, one in exon 7, two in intron 7, and one 
in exon 8) (27) but none of these changes cause modifications in the amino acid of the 
SMN protein (28).  
SMN and splicing. 
A difference between SMN1 and SMN2 genes is the C to T transition in exon 7, 
that reduces the efficiency of exon 7 inclusion in the SMN2 transcript, resulting in a 
truncated protein with altered activity (29) (30).  
In fact, in eukaryotes, the immature transcript is produced just after the gene 
transcription (pre-mRNA) and it contains exons and introns. Then the pre-mRNA 
undergo splicing, a process that removes introns and joins exons to produce mature 
messenger RNA (mRNA) (figure 3).  
 
Figure 3: (a) Diagram of a pre-mRNA  and (b)a mature mRNA. 
www.web books.com/MoBio/Free/Ch5A4.htm. 
 
In pre-mRNA the boundary intron-exon is defined by the splice sites that are 
located at the 5 'and 3' of each intron (figure 4) and by an internal signal, branch site, 
characterized by the presence of adenine (figure 4) (31). 
11 
 
 
Figure 4: Representation of the splicing sites of a pre-mRNA. 
www.web-books.com/MoBio/Free/Ch5A4.htm. 
 
The splicing is catalysed by the spliceosome, which contains five small 
ribonucleoproteins (U1, U2, U4, U5, and U6 snRNPs) and many other proteins (figure 
5) (32). 
 
Figure 5: Native Spliceosome model. Ziv Frankenstein et al., 2012. 
 
Except the ribonucleoprotein U6, whose biogenesis is thought to be only in the 
nucleus (33), the other snRNPs are transcribed in the nucleus, exported to the cytoplasm 
and assembled, by the SMN complex (34), with the Sm proteins (B/B0, D1, D2, D3, E, F 
and G) (figure 6) (35). 
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Figure 6: snRNP assembly scheme. Séverine Massenet et al., 2002. 
 
Then, the snRNPs partially mature (36), return to the nucleus and accumulate 
themselves in Cajal Bodies (CB) (figure 6), where they continue their maturation and 
when this is completed, they move to nuclear speckles, in which will remain as a 
reserve, until the time of splicing (37) (38) (39). 
In eukaryotic cells, alternative splicing also occurs in addition to constitutive 
splicing.  
This process is very important in regulating the eukaryotic transcriptome and 
often, the different mRNA isoforms of a same gene in different tissues derived from 
alternative splicing (40). It is also occurs very frequently in the nervous tissue (41). 
Alternative splicing can be done in several ways (figure 7), for example in 
humans can occur through intron retention, exon skipping (the most common event), 3’ 
alternative splicing, 5’ alternative splicing, mutually exclusive exons, alternative first 
exons, and alternative last exons (42). 
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Figure 7: Diagram that representing the different possible events of alternative splicing. 
 E Z, Wang L, Zhou J., 2013. 
 
Special sequence elements, near the splice sites, activate or repress alternative 
splicing (20) through the recognition of cis elements by trans factors (figure 8) (40). 
 
Figure 8: Diagram showing the cis regions of transcript and trans factors that recognize them. 
 http://www.h-invitational.jp/h-dbas/as_mechanism.jsp. 
 
In particular, trans factors examples are the SR proteins, that can cause the non-
inclusion of the exons (43) and the hnRNPs that often act as repressors (figure 8) (44) (45). 
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Conversely, the cis sequences are (figure 8) Exonic Splicing Enhancers (ESEs), 
Exonic Splicing Silencers (ESSs), Intronic Splicing Enhancers (ISEs) e Intronic 
Splicing Silencers (ISSs) (46) (47) (48). 
In fact the C/T transition, at position +6 in exon 7 in SMN2 gene, creates an 
exonic splicing silencer (ESS) that is recognized by hnRNP A1 and this results in the 
exon 7 non-inclusion (figure 9) (49). 
 
Figure 9: Schematic representation of SMN2 alternative splicing. 
www.thelancet.com/journals/lancet/article/PIIS0140673608609216. 
 
This change is the cause of the formation of a shorter protein (SMNΔ7) which is 
less stable (29) (48).  
A strong ESE is in the central part of exon 7; it is recognized by different 
splicing factors, that help inclusion of exon 7 (figure 9). This is responsible to SMN2 
full length presence in 10% of cases and this explains why the number of copies of 
SMN2 influences the SMA phenotype (50). 
Therefore a decrease in SMN1 protein is present in SMA and specifically in 95% 
of cases the SMN1 gene is absent for exon 7 SMN1 homozygous deletion (51) (27). In 5% 
of cases other mutations are in the SMN1 gene, such as small deletions, mutations at 
sites of splicing and missense mutations (52). These mutations include deletion of 4 or 5 
bp in exon 3, an 11 bp duplication in exon 6, five different missense mutations in exons 
6 and 7 (53). 
The splicing of SMN2 is also regulated by hnRNP Q (figure 10) (54) (56). 
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Figure 10: Schematic of some factors that regulate splicing of SMN1 and SMN2.  
Thomas W. Bebee, Jordan T. Gladman, and Dawn S. Ch, 2011. 
 
The SMN protein links itself and it maintains this ability in case of mild 
mutations. Conversely, in case of exon 7 loss and missense mutations in exon 6, it loses 
this function, causing severe SMA phenotype (56). This happens because SMN is not 
able to oligomerize and it is immediately degraded and this causes low levels of the 
protein  (57). 
The correction of SMN2 splicing to increase the levels of SMN2 exon 7 inclusion 
can be achieved by several strategies, for exsample antisense oligonucleotides and 
trans-splicing. 
Splicing of SMN is also regulated by TDP-43 protein, in fact, it has been found 
that if TDP-43 decreases the SMN lacking exon 7 increases (58). 
Finally, in a recent study, it was shown that in human neuronal and non-neuronal 
cells, both the SMN2 and the SMN1 gene, have different isoforms of transcripts, that are 
formed by different alternative splicing events that cause, for example, the 3 or 5 exon 
non-inclusion, thus these transcripts are smaller than the full SMN transcript (30). 
SMN protein. 
SMN is a protein of 294 amino acids. It contains distinct functional domains that 
mediate various interactions, including interactions with itself, with the Sm proteins, 
with other proteins and with nucleic acids (figure 11) (59). 
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Figure 11: Representation of the SMN exons and SMN domains.  
A H M Burghes and C E Beattie, 2009. 
 
As it is possible see in the figure 11, the Tudor domain of SMN protein is 
encoded by exon 3. This domain has been found in several proteins and in SMN protein 
it is required to interact with the Sm proteins (60). 
The region of SMN encoded by exon 2 (figure 11) is necessary and sufficient to 
mediate its nucleic acid-binding activities, to interact with Gemin2 and it participates to 
self-oligomerization (56) (61) (62). 
Conversely, the 6 and 7 SMN exons contain the information for the formation of 
the portion of the protein required for self-oligomerization (57) (figure 11) . 
The SMN protein is part of SMN-COMPLEX (figure 12). This complex is formed by 
SMN protein and other 7 proteins (Gemin2-8) and it is very important for the biogenesis 
of specific snRNP (63). 
 
Figure 12: Representation of SMN COMPLEX. Stephanne Levin et al., 2010. 
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SMN protein interacts with Sm proteins through its Tudor domain (64) and it 
binds specifically them to snRNP (figure 13) (65).   
 
Figure 13: Image that explains the different functions of the SMN protein in neurons.  
C Fallini, G J Bassell and W Rossol, 2012. 
 
A recent study has suggested that FUS mutations have a significant effect on 
snRNP localization (66). 
Furthermore, the assembly of snRNP depends on the SMN amount present and it 
is the reason that SMA individuals have a decreased ability to assemble these 
ribonucleoprotein (67). 
In addition Zhang Z. et al. have shown that a loss of SMN level greater than 80% 
is necessary to cause a significant change in the levels of snRNAs or cause the death of 
cells in culture (68).  
It has also been shown that siRNA silencing of SMN has an effect on the snRNAs 
U2, U12 and U4atac and the same happens in SMA patients (69), however it is not clear 
what SMN-mediated mechanism causes localized damage in motor neurons. 
To understand this localized effect, Lotti F. analyzed the role of splicing U12-
SMN dependent, in the regulation of motor circuits. This study was done in Drosophila, 
which has a gene, stasimon, that has U12 introns. This gene is a SMN target and it 
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encodes to a protein necessary to a normal synapse in cholinergic neurons. The 
reduction of SMN protein has an effect on stasimon splicing and then on its expression 
in motor circuits. This could explain the localized effect in motor neurons. Stasimon’s 
homologous genes have been found in human, mouse, zebrafish and other species (19).  
Moreover, each cell has specific splicing factors and therefore the decrease of 
SMN may have a unique effect on snRNPs in each case (68). 
Janina Rafatoska et al. analyzed the same problem in amyotrophic lateral 
sclerosis and they gave an explanation for the lack of effect of protection by the SMN, 
assuming that other components of the SMN complex may be involved, such as gemin  
proteins (70). 
Wan L. et al. discovered that ROS (reactive oxygen species) inhibit the SMN 
complex activity in a dose dependent manner (71) and oxidative stress is one of the 
possible causes of amyotrophic lateral sclerosis (ALS). 
The SMN protein was also found in the axon (figure 13) (72) and it is not 
associated with the Sm proteins here then it probably has a different function (73). 
TAR DNA-binding protein of 43 kDa (TDP 43) and RNA 
binding protein fused in sarcoma/translated in liposarcoma 
(FUS/TLS). 
The TARDBP and the FUS/TLS genes, are mutated in some cases of ALS (74) (75) 
and they form cytoplasmic aggregates (granules) through independent mechanisms (76). 
Missense mutations in TARDBP, the gene encoding TDP-43, are a known cause 
of  FTLD and of familial and sporadic ALS, ~5% of ALS (77) (78) (79). 
The human TDP-43 gene, which is located on chromosome 1 and contains 6 
exons, is alternatively spliced to generate at least four isoforms.  
The TDP-43 protein has 414 amino acid. It contains two highly conserved RNA 
recognition motifs (RRM1 and RRM2) and a glycine-rich C-terminal sequence (figure 
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14). This last region mediates the TDP-43 protein interactions (80) whereas the RRMs 
domains mediate RNA recognition (81). 
 
Figure 14: Diagram of the domains of the TDP 43 protein.  
 Casey Cook et al., 2008. 
 
The TDP-43 protein interacts with many proteins and this suggests that it is a 
multifunctional protein, mostly associated with transcription, splicing and translation 
(82) (80).  
For example, it acts as a transcriptional repressor and inhibits exon skipping 
through the specific recruitment to 3’ splice sites (83). It was also discovered that 
regulates alternative splicing of its own transcript (81). 
The FUS gene is mutated in ~4% of familial and rare sporadic ALS cases (79). 
Most mutations are missense mutations except for example, a de novo splice-site 
mutation that leading to the skipping of exon 14 and this products a truncated FUS/TLS 
protein (p.G466VfsX14) (84). 
FUS is a protein formed by 526 amino acid and encoded by 15 exons. It is 
composed of an N-terminal domain enriched in glutamine, glycine, serine and tyrosine 
residues (QGSY region), a glycine-rich region, an RRM domain, multiple 
arginine/glycine/glycine (RGG) repeats in an arginine and glycine-rich region and a C-
terminal zinc finger motif ( figure 15) (85). 
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Figure 15: Diagram of the domains of the FUS protein. 
 Clotilde Lagier-Tourenne et al., 2010. 
 
The FUS protein interacts with SMN protein in mouse neurons and in HeLa 
cells. Mutations in FUS would have affect on this interaction causing axon defects (85) 
(86). 
Furthermore it was shown that in case of FUS mutation (R521C FUS), the FUS 
protein undergoes a relocalization, in primary cultures of human fibroblasts of ALS 
patients, accumulating itself in the cytoplasm (87). 
Neuronal cytoplasmic protein aggregation and defective RNA metabolism thus 
appear to be common pathogenic mechanisms involved in ALS. 
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RESEARCH OBJECTIVES. 
As it was mentioned in the introduction, the amyotrophic lateral sclerosis (ALS) 
pathogenesis is not yet completely clear. 
So the PhD research aim was to provide a further contribution to the knowledge 
on the ALS molecular basis, with particular attention to the role of SMN. 
All studies were done at the Neurochemistry Laboratory, Department of 
Experimental Biomedicine and Clinical Neurosciences, University Hospital "Paolo 
Giaccone" in Palermo. 
The research program was: 
 Study of the SMN gene through PCR-RFLP in patients with ALS and in 
control subjects. 
 Molecular characterization of the SMN protein isoforms to understand 
whether specific isoforms are involved in the ALS pathogenesis. 
  Characterization of  FUS and TDP-43 proteins, involved in ALS and that 
they are SMN potential interactors. 
 Analysis of the SMN, FUS and TDP-43 proteins localization to study if 
any changes occur in case of particular conditions such as differentiation 
or mutations. 
 Study of the SMN interactions with wild type and mutant FUS protein to 
understand if a change of this condition can help trigger the ALS. 
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CHAPTER 1- SMN GENE ANALYSIS. 
Introduction and objectives. 
We decided to analyze SMN gene because in literature there are many studies on 
this topic. These antecedent studies were done on patients with spinal muscular atrophy 
(SMA). 
As shown in figure 16, the two copies of SMN gene are identical except 5 
nucleotides (88) and these nucleotide changes are exploited by the PCR-RFLP technique. 
 
Figure 16: Representation of the nucleotide differences between the SMN1 and SMN 2 genes.  
Balraj Mittal, 2012. 
 
 
Specifically, PCR products of exon 8 from SMN1 and SMN2 genes were 
distinguishable by the presence of the recognition site for the restriction enzyme DdeI 
(figure 17).In fact this site is absent in SMN1 gene but is present in SMN2 gene.  
Conversely, for the recognition of exon 7 of SMN1 and SMN2 genes, a 
mismatched downstream oligonucleotide primer is used. It recognizes the region 
adjacent to the SMN2 exon 7 variant site (figure 17). This creates a restriction site, that 
is recognized by the enzyme DraI. In particular, how is shown in figure 17, the change 
creates a Dra I site (TTTAAA) because the third T nucleotide of the sequence is present 
only in the SMN2 gene, thus the enzyme Dra I cuts only the SMN2 amplified PCR 
product (89) (90). 
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Figure 17: Representation SMN 7 and 8 exons RFLP-PCR specific method. 
 Guey-Jen Lee-Chen et al., 1996. 
 
Numerous studies have been done to understand the role of SMN in amyotrophic 
lateral sclerosis. 
For example, Veldink JH et. al., in 2001, analyzed deletions of 7 and 8 exons of 
SMN1 and SMN2 genes in sporadic amyotrophic lateral sclerosis (ALS). They showed 
the presence of a homozygous SMN2 deletion. Then they suggested that the SMN2 gene 
can act as a prognostic factor because patients with a homozygous SMN2 deletion had a 
shorter median time of survival (91). 
Corcia P. et al. in 2002, studied the same topic and they discovered that 16% of 
amyotrophic lateral sclerosis patients had an abnormal copy number of the SMN1 gene 
(1 or 3 copies) (92). Then in 2006, they explored the frequency of abnormal SMN1 gene 
copy numbers, advancing the conclusion that abnormal SMN1 gene copy numbers is a 
genetic risk factor in ALS (93). 
After a couple of years, we studied the SMN1 and the SMN2 genes, by PCR-
RFLP method, considering the Lefebvre and Van Der Steege protocols.  
Materials and Methods. 
SAMPLES COLLECTION: In our laboratory 46 whole blood samples in tubes 
with EDTA have been collected. Specifically, we collected 31 ALS samples, 2 SMA 
samples and 13 neurological controls samples. 
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PCR-RFLP METHOD: Genomic DNA was extracted from peripheral blood 
using Puregene kit . 
Polymerase chain reaction (PCR) amplification of 7 and 8  SMN exons was done 
using 250 ng DNA, preparing from time to time an appropriate mix and executing a 
different amplification program, based on the type of exon that we wanted to amplify. 
In particular, the mix was prepared using 0.5 U Taq polymerase (Euroclone), 
200 μM dNTPs (Euroclone), 50 mM MgCl2 (Euroclone), 1X reaction buffer magnesium 
free  (Euroclone), 100 pmol primers specific (Amersham pharmacia biotech), all diluted 
with water to obtain a final volume of 20 µL. 
To amplify the 7 SMN exon we used the specific primers (figure 17): 
 forward intron 6 primer R111:5’-AGACTATCAACTTAATTTCTGATCA-3’(94); 
 reverse mismatch primer X7-Dra: 5’-CCTTCCTTCTTTTTGATTTTGTTT-3’ (95). 
The PCR performed by 35 cycles , using a specific amplification program:  
initial denaturation: temperature was set to 94 °C for 4 minutes; 
denaturation: temperature was set to 94 °C for 1 minute;  
annealing: temperature was set to 55 °C for 1 minute;  
elongation: temperature was set to 72 °C for 1 minute;  
final elongation: temperature was set to 72 °C for 7 minutes. 
 
To amplify the 8 SMN exon we used the specific primers (figure 17): 
 forward primer 541C960: 5’- GTA ATA ACC AAA TGC AAT GTG AA - 3’; 
 reverse primer 541C1120: 5’- CTACAACACCCTTCTCACAG - 3’. 
The PCR performed by 35 cycles, using a specific amplification program: 
initial denaturation: temperature was set to 94 °C for 4 minutes;  
denaturation: temperature was set to 94 °C for 1 minute; 
annealing: temperature was set to 59 °C for 1 minute;  
elongation: temperature was set to 72 °C for 1 minute;  
final elongation: temperature was set to 72 °C for 7 minutes. 
The amplified products were digested, overnight at 37 °C, with appropriate 
restriction enzymes and buffer, specifically we used : 
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 Dra I and NE Buffer 4 (BioLabs) for 7 SMN exon; 
 Dde I and NE Buffer 3 (BioLabs) for 8 SMN exon. 
The after day , the digested products were electrophoresed on 2% agarose gel for 
further analysis. 
Results and discussion. 
All experiments were performed using ALS samples, positive control (SMA 
subject), neurological control (patient with neurologic disease but it does not involving 
motor neurons ) and negative control (there was not DNA but water).  
The results of the study on 7 SMN exon reflect the below image (figure 18). 
Many experiments have been and in each the positive control, always appeared a single 
band (176 bp), corresponding to SMN2 gene. However two bands always appeared that 
correspond to SMN1 (188 bp) and SMN2 (176 bp) in each neurological controls and in 
each ALS patients.  
 
Figure 18: Result experiment of 7 SMN  exon RFLP - PCR.  
C+ = positive control; CN = neurological control; ALS = patient with ALS;  C - = negative control. 
 
 
The figure 19 shows the result obtained from the study of 8 SMN exon. 
In the positive control always appeared two bands (122 bp and 78 bp), which 
correspond to the SMN2 gene, conversely always three bands ( 200 bp; 122 bp and 78 
bp) are in neurological controls and in ALS patients, that correspond to the SMN1 and 
SMN 2 genes (figure 19). 
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Figure 19: Result experiment of 8 SMN  exon RFLP - PCR.  
C+ = positive control; CN = neurological control; ALS = patient with ALS;  C - = negative control. 
 
All results are summarized in the following table (tab 1). 
 
Tab. 1: Summary of the results obtained from the study of 7 and 8 SMN exons with RFLP-PCR.  
C+ = positive control; CN = neurological control; ALS = patient with ALS. 
 
Conclusions. 
The results obtained from the analysis of SMA patients, that we used as positive 
control, correspond to the data available in the literature (94). In fact, all SMA patients 
analyzed show deletion of the SMN1 gene but this deletion is never present in 
neurological control and in ALS samples. Conversely the SMN2 gene is present in all 
samples. 
Therefore, these data indicate that the SMN1 gene though involved in the SMA 
pathogenesis, it is not involved in ALS. Then, we done a further contribution to 
understand the molecular basis of this disease. In fact, there are still conflicting ideas 
about the role of the SMN gene. 
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In the future, it would interesting to see if the number of copies of SMN genes 
varies or if there are variations in their promoter that could alter the transcription and 
then cause disease. 
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CHAPTER 2- RESEARCH OF ISOFORMS OF SMN, FUS 
AND TDP43 PROTEINS IN HUMAN LEUKOCYTES, HeLa 
CELLS AND SH-SY5Y CELLS. 
Introduction and objectives. 
We studied the different isoforms of SMN, FUS, TDP-43 proteins to have a 
starting point to carry out more specific surveys for each isoform. 
The SMN is a ubiquitous protein that is found in both the cytoplasm and the 
nucleus of the cells and which has different isoforms in different cell types (96) (97). 
La Bella V. et al. in 2000, showed that two isoforms of SMN arise in primary 
brain neurons of rat and in motor neurons. These have molecular mass of 32 kDa and of 
35 kDa. Conversely, in mouse 3T3 fibroblast there is only a 42 kDa SMN isoform. 
Then, they affirmed that the different isoforms have a different subcellular localization 
and specifically the 32 kDa isoform is in citoplasm (97). The same group in 2006 
explained that the smaller isoform is derived by proteolytic cleavage (98). 
Many studies were done on the SMN isoforms and a lot of them have been 
identified  isoforms with molecular mass between 45 kDa and 24 kDa. In addition the 
expression of these isoforms changes during the development in various tissues in rat 
(99). 
Sossi V. et al., conducted studies on the same issue, suggesting that the SMN 
RNA isoform that lost the exon 3 produces a protein lacking 67 amino acids, which has 
a molecular mass about 31 kDa. 
An axonal SMN isoform (a-SMN) was also discovered. It is an alternatively 
spliced SMN form that is preferentially encoded, in humans, by the SMN1 gene. In 
addition 2b and 3 exons are important for its formation. Its molecular mass is less than 
that of the canonical SMN protein (100). 
As it has been already described in the introduction, TDP- 43 protein found 
mutated in sporadic and familial ALS. 
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It was shown that, a TDP-43 isoform with a slightly smaller a TDP-43 isoform 
with a slightly smaller molecular mass is in the cytoplasm of leukocytes of ALS 
patients. However the same levels were found both in the whole cell lysates of the ALS 
patients and of the controls (101). 
Guo W et al, conversely found an greater molecular mass isoform (about 74 
kDa) compared to that expected in brain of subjects with frontotemporal lobar 
degeneration (FTLD), other condition in which TDP-43 has mutated (102). 
Finally, a very small isoform of TDP43 protein, about 25 KDa was found. It 
thought to be toxic (103) (104). In addition the 35-kDa TDP-43 isoforms is assembled in 
stress granules, cellular structures that package mRNA and RNA-binding proteins 
during cell stress (105). 
Mutations in the FUS gene are also associated with ALS. The FUS protein was 
detected by western blot as an approximately 72 kDa protein in both human and mouse 
brains (106). 
Materials and methods. 
LEUKOCYTE COLLECTION: In our laboratory whole blood samples in EDTA 
tubes has been collected, the leukocytes were extracted from each fresh sample 
immediately.  
The leukocytes extraction was done by a precipitation with 3% dextran for one 
hour at room temperature and by centrifuging for 10 minutes at 3500 RPM. Then the 
pellet was resuspended in cold 0.9% NaCl and it centrifuged for 8 minutes at 3500 
RPM. Later the pellet was resuspended with a cold solution of 0,05% KCl and it 
centrifuged for 8 minutes at 3500 RPM, so many times up to have a clean pellet, once 
this accomplished, it was resuspended in cold 0,05% KCl and centrifuged for 5 minutes 
to 5000 RPM. The pellet was used immediately or was stored at - 80 °C until use. 
CELL CULTURE: HeLa (Human epithelial carcinoma cell line) cells were 
grown in 75 cm 
2
 Falcon flask filled in Dulbecco’s modified Eagle’s medium (DMEM, 
Euroclone) with 10%  fetal calf serum (Euroclone), 2 mM L-glutamine (Euroclone) , 
100 U/ penicillin and 100 µg streptomycin (Euroclone). 
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SH-SY5Y (human neuroblastoma) cells were grown in a 75 cm 
2
 Falcon flask 
filled in Dulbecco’s modified Eagle’s medium (DMEM, Euroclone) supplemented with 
Nutrient Mixture F-12 (1:1, GIBCO) and with 10% fetal calf serum (Euroclone), 2 mM 
L-glutamine (Euroclone), 100 U/ penicillin and 100 µg streptomycin (Euroclone). 
PROTEIN EXTRACTION : The lysis of leukocytes and the lysis of the cells in 
culture was done on ice, using a specific buffer (10 mM Tris-HCl, 1 mM EDTA, 200 
mM NaCl, 0.2% SDS) with protease inhibitors (pepstatin, antipaina, leupeptin and 
PMSF). Then the cell suspension has undergone a brief sonication and it centrifuged at 
5000 RPM for 5 minutes at 4 °C. Then the supernatant was recovered. 
SUBCELLULAR FRACTIONATION OF CELLS: To make this process we 
used the digitonin 0.04%, it was resuspended in RSB 100 buffer (10 mM Tris-HCl pH 
7.4, 100 mM NaCl, 2.5 mM MgCl2).  
The digitonin stock solution was dissolved in ethanol because the alcoholic 
solution of digitonin forms insoluble complexes with cholesterol (plasma membrane) 
but it does not form these with cholesterol esters and then it preserves the nuclei. 
The samples were kept on ice in all stages of this process. In particular, the 
culture medium was aspirated from the cells and they were washed with D-PBS 
Dulbecco's Phosphate Buffered Saline (Euroclone). Then these cells or leukocites are 
resuspended in digitonin 0.04%, supplemented with protease inhibitors (pepstatin, 
antipaina, leupeptin and PMSF) and they were incubated for 10 minutes at 4 °C in 
constant shaking. Afterward the cells were lysed by repeated passages in 25 G needle 
and then they were centrifuged at 900 g for 10 minutes at 4 C. The pellet obtained 
corresponded to the nuclei and the supernatant corresponded to the cytoplasm. Later the 
nuclei were observed with optical microscope using a 40 X objective (figure 20) and 
then they were resuspended in RSB 100 buffer with inhibitors of protease. Protease 
inhibitors were only added in the cytoplasmic fraction. 
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Figure 20: SH-SY5Y (A) and HeLa cells (C), optical microscope, 10 X; nuclei of SH-SY5Y cells (B) and nuclei of 
HeLa cells (D), optical microscope, 40 X. 
 
The samples were used immediately for Western blotting experiments. 
SDS-PAGE AND WESTERN BLOTTING ANALYSIS: All samples were 
diluted in a ratio of 3:1 with sample buffer and they were denatured at 95 °C for 5 
minutes. Then the samples were carried, in equal volume, in polyacrylamide 12 % gel 
and they were underwent to SDS-PAGE. 
Various primary antibodies were used for Western Blotting: the SMN antibody 
(purified mouse Anti-SMN, BD Transduction Laboratories™); the FUS antibody (FUS 
monoclonal antibody, Proteintech Group) and the TDP-43 antibody (TARDBP 
polyclonal antibody, Proteintech Group). Conversely, the secondary antibodies used 
are: anti mouse and anti rabbit, both conjugated to horseradish peroxidase (Sigma-
Aldrich) .  
Finally, the membranes were exposed to ECL (Thermo Scientific), the data 
capture was done to Imaging system ChemiDoc-it 410 from UVP (BioRad) and the 
images were analyzed with VisionWorks ® Life Science Software . 
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Results and discussion. 
We did subcellular fractionation to study the protein isoforms and to understand 
in which cellular fraction these are. 
In particular, 34 samples leukocytes were fractionated, including 16 neurological 
controls, 2 healthy controls and 16 ALS subjects.  
Initially, leukocytes of neurological controls were analyzed to understand how 
SMN protein is expressed when disease is not present. 
The experiment was repeated three times and the result was always the same: 
different SMN isoforms. All isoforms are both in the total cells lysed and in the nuclear 
fraction but the cytoplasmic fraction has not the smaller isoform. Furthermore the larger 
SMN isoforms (40 kDa) seems to have a higher level of expression in the nuclear 
fraction (figure 21). 
 
Figure 21: In the first lane the molecular weight markers was loaded (M); in the second lane western blotting for 
SMN from whole leukocytes of a neurological control (T), third lane western blotting cytoplasmic fraction of the 
same subject (C) and in the fourth lane nuclear fraction (N). Purified mouse Anti-SMN (BD Transduction 
Laboratories™1:5000); anti mouse 1: 10000. 
 
 
Later, ALS leukocytes were analyzed but this experiment was done only one 
time. The result, that does not appear, shows the absence of the higher molecular weight 
SMN isoform. The data need to be confirmed but they suggest that a isoform of SMN 
protein is lost in patients with ALS. If this result will be confirmed, we can say that 
SMN gene is not compromised in ALS but the SMN protein is modified in this disease. 
The same experiments were done to study TDP-43 isoform. From the figure 22 
it is possible to see that multiple TDP-43 isoforms are in leukocytes of neurological 
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controls but the one with higher molecular weight is found only in the nucleus. These 
experiments were performed twice and each time the result was the same. 
 
Figure 22: In the first lane molecular weight markers was loaded (M); in the second lane western blotting for TDP-
43 from whole leukocytes of a neurological control (T), third lane western blotting cytoplasmic fraction of the same 
subject (C) and in the fourth lane nuclear fraction (N). TARDBP polyclonal antibody (Proteintech Group 1:10000); 
anti rabbit 1:10000. 
 
The experiment in leukocytes of ALS subjects was done only one time and the 
result seems to be the opposite of the result obtained from the control subjects. In fact, 
in the nucleus only the 43 kDa isoform appears and it seems that there is a smaller 
amount of protein in nucleus than cytoplasm (figure 23).  
 
Figure 23: In the first lane western blotting for TDP-43 from whole leukocytes of a ALS subjects (T), second lane 
western blotting cytoplasmic fraction of the same subject (C) and in the third lane nuclear fraction (N). TARDBP 
polyclonal antibody, Proteintech Group 1:10000; anti rabbit 1:10000. 
 
 
This element must be confirmed but it recalls what is reported in the literature. 
Namely, that when TDP-43 is mutated, it translocates to the cytoplasm. Conversely, we 
analyzed ALS patients who do not have this mutation. Then if these data will be 
confirmed, we can say that the TDP-43 translocates to the cytoplasm even if mutation is 
not present.  
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Finally, the same experiments were done for FUS protein. Many isoforms were 
seen also here. In particular, an isoform of 68 kDa is in the nucleus and it is not present 
in the cytoplasm (figure 24). 
 
Figure 24: In the first lane was loaded molecular weight markers (M); in the second lane western blotting for FUS 
from whole leukocytes of a neurological control (T), third lane western blotting cytoplasmic fraction of the same 
subject (C) and in the fourth lane nuclear fraction (N). FUS monoclonal antibody (Proteintech Group 1:10000); anti 
mouse 1:10000. 
 
 
These three proteins have been also studied in human cell cultures (HeLa and 
SH-SY5Y cells) to have the models on which to do further analysis to understand more 
about their pathways. 
Multiple isoforms of each protein studied are in these cells.  
In detail, an only SMN isoform (45 kDa) is in SH-SY5Y cells. Conversely, many 
isoforms of FUS and TDP-43 proteins are in the same cells and they are mainly present 
in the nucleus (figure 25). 
 
Figure 25: In the first lane western blotting for SMN from nuclear fraction of SH- SY5Y cells and the in second lane 
there is the cytoplasmic fraction of the same cells, third lane western blot for FUS from nuclear fraction of SH-SY5Y 
cells and in the fourth lane there is cytoplasmic fraction of the same cells, in the fifth lane western blotting for TDP-
43 from the nuclear fraction of SH- SY5Y cells and in sixth lane there is cytoplasmic fraction of the same cells , in the 
lastly lane there is molecular weight marker. Purified mouse Anti-SMN (BD Transduction Laboratories™1:5000), 
anti mouse 1: 10000; FUS monoclonal antibody ( Proteintech Group 1:10000), anti mouse 1:10000; TARDBP 
polyclonal antibody (Proteintech Group 1:10000), anti rabbit 1:10000. 
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In HeLa cells, the SMN protein is present in a single isoform about 44 kDa both 
in the nucleus and in the cytoplasm (figure 26). In the same cells, the FUS protein is the 
same both in the nucleus and in the cytoplasm but it appears to be higher in the nucleus 
than in the cytoplasm (figure 26). 
 
Figure 26: a) In the first lane western blot for SMN from nuclear fraction of HeLa cells, in the second lane western 
blot for SMN from the cytoplasmic fraction of the same cells. Purified mouse Anti-SMN (BD Transduction 
Laboratories™1:5000); anti mouse 1: 10000. b) In the first lane western blot for FUS from nuclear fraction of HeLa 
cells, in the second lane western blot for FUS from the cytoplasmic fraction of the same cells. FUS monoclonal 
antibody (Proteintech Group 1:10000); anti mouse 1:10000. 
 
 
Conclusions. 
We confirm that different SMN isoforms are in the various cell types analyzed, 
human leukocytes , HeLa cells and neuroblastoma cells (SH-SY5Y).  
In fact, in human leukocytes the SMN protein is present in 40 kDa, 30 kD, 20 
kDa and 15 kDa isoforms; in HeLa cells the same protein is only 44 kDa isoform and in 
SH-SY5Y cells the 45 kDa SMN isoform is the most expressed. 
La Bella et al in 2004, have explained the existence of these isoforms showing 
that the SMN protein undergoes post-translational modifications. Rat SMN mRNA does 
not undergo alternative splicing; on the contrary, the human SMN mRNA can undergo 
this process. This could give another explanation to the existence of different SMN 
isoforms but to assert this RT-PCR experiments must be done. 
In addition, we show that different SMN isoforms are in the various cell 
compartments. Especially, the differences are between the nucleus and the cytoplasm of 
human leukocytes (figure 21), in particular the smaller isoform is absent in the 
cytoplasm and the larger one seems to be less expressed in the same cell compartment.  
Then we analyzed the TDP-43 expression in human leukocytes and 
neuroblastoma cells (SH-SY5Y). Multiple TDP-43 isoforms are in leukocytes of 
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neurological controls (figure 22) and the isoform with higher molecular weight was 
found only in the nucleus.  
Conversely, the experiment in ALS leukocytes (figure 23) shown that only the 
43 kDa TDP- 43 isoform is in the nucleus of these cells and a less amount of it is 
present in the nucleus than in the cytoplasm. The last data must be confirmed but if 
these data will be confirmed. 
In neuroblastoma cells (figure 25), multiple isoforms of TDP-43 appear and both 
in the nucleus and in the cytoplasm the 43 kDa TDP- 43 isoform is the most expressed. 
Finally, we have studied the FUS expression in human leukocytes, in 
neuroblastoma ( SH-SY5Y) and in HeLa cells. In human leukocytes (figure 24) the FUS 
protein is present in different isoforms and in particular the 68 kDa specific isoform was 
found in the nucleus. However difference is not present between control and ALS 
patients analyzed. The same results were found in HeLa (figure 26) and in SH-SY5Y 
cells (figure 25).  
Therefore, SMN, TDP-43 and FUS proteins have various isoforms that are often 
found in different cellular compartments. Probably, as they are multifunctional proteins, 
each isoform corresponds to a different protein function.   
In addition, in case of ALS (figure 23 and other data not shown) some SMN and 
TDP43 isoforms seem to be lacking or moving into the cytoplasm. These data must be 
confirmed but suggest that although in the pathogenesis of ALS the mutations are not in 
the DNA, an involvement of the studied molecules may be at the protein level. 
For this reason, in the future we will be studied the meaning of these isoforms, 
paying attention to the post-translational modifications, through specific assays, and 
analyzing alternative splicing, through RT-PCR studies.  
Experiments on leukocytes ALS will be also repeated several times to 
understand whether a difference in the expression of isoforms is present between 
controls and diseased patients and if this difference may contribute to the pathogenesis 
of ALS . 
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CHAPTER 3- FUS, TDP43 AND SMN PROTEINS 
LOCALITAZION IN HeLa AND SH-SY5Y CELLS. 
Introduction and objectives. 
After studying SMN, TDP-43 and FUS protein isoforms and after showing that 
they often have a different distribution in the cells, the analysis was continued by 
immunofluorescence. We done this to study their subcellular localization in human cell 
lines: HeLa and in neuroblastoma cells ( SH-SY5Y). 
Already in 1996, Liu Q and Dreyfuss G. shown that the SMN protein was 
expressed in not only Gems of HeLa cells but also in the cytoplasm (107).  
It has also been seen that the  inhibition of the SMN expression by RNA 
interference leads to defects in Cajal body formation in HeLa cells (108). 
The Cajal bodies (CBs) and the Gems (gemini of Cajal bodies) are nuclear 
structures that are not bounded by a membrane and in many cell types the two structures 
co-localize (109). 
The CBs are generally found in nucleoplasm but they have been detected in 
nucleolus of human breast carcinoma cells and of brown adipocytes. A specific CBs 
marker is p80-coilin protein (109). 
The CBs are dynamic structures; in fact they disassemble during mitosis and 
they reassemble in G1 phase of cell cycle (110). 
The snRNPs (small nuclear ribonucleoproteins) move first through the Cajal 
bodies, then pass to the speakles and finally reach the nucleolus (111) (112). 
In the nucleus, the SMN has been proposed to have a direct role in pre-mRNA 
splicing, possibly involving recycling of splicing complexes (113). 
The Gems are the nuclear site of SMN accumulation. In one study it was 
observed that these bodies are extremely rare in undifferentiated cells but they are more 
readily detected upon differentiation (114).  
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In another study, it was found that the simultaneous non-inclusion of exon 5 and 
exon 7 in SMN leads to the decrease in the number of Gems and that the amino-terminal 
domain of SMN is also essential for the correct cellular distribution (115). 
In 2008, it was demonstrated that TDP-43 protein continuously shuttles between 
the nucleus and the cytoplasm, in a transcription-dependent manner. Specifically, it was 
shown that C-terminus portion of this is essential for cellular localization, in fact the 
disruption of the RNA-recognition domain causes the decrease of TDP-43 protein in the 
nucleoplasm. Then, its C-terminus portion and its RRM1 domain are essential for 
correct cellular localization. If mutated, this protein accumulates in stress granules (116) 
(117). 
In ALS, Gems are lost and Hitomi Tsuiji et al. found that TDP-43 is located in 
these bodies of many cells (118). Furthermore, in a recent study it was found that TDP-43 
controls the distribution of SMN in Gems of motor neurons of TDP43 transgenic mice 
(119). 
The FUS protein is also mis-localized in ALS (117). In fact, FUS is localized 
mainly in the nucleus but mutations in the C-terminus of FUS show neuronal 
cytoplasmic FUS-positive inclusions, because a signal which is needed for nuclear 
import is in this domain (120). 
Materials and methods. 
CELL CULTURE: As shown in chapter 2. 
IMMUNOFLUORESCENCE: The HeLa cells and SH-SY5Y cells are grown on 
cover slips in 4-well plate, washed with cold D-PBS Dulbecco's Phosphate Buffered 
Saline (Euroclone), fixed for 30 minutes with 4% paraformaldehyde at room 
temperature, washed 3 times with cold D-PBS Dulbecco's Phosphate Buffered Saline 
(Euroclone), treated for 15 minutes with 50 mM ammonium chloride (NH4Cl) at room 
temperature to decrease the autofluorescence of paraformaldehyde, permeabilized with 
PBS TRITON 0.5% for 10 minutes at room temperature and incubated for one hour at 
room temperature with 2% BSA to block nonspecific sites. Later specific primary 
antibodies were added and they were kept overnight at 4 °C, the specific primary 
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antibodies used are: SMN antibody (purified mouse Anti-SMN, BD Transduction 
Laboratories™); FUS antibody (FUS polyclonal antibody, Proteintech Group); TDP-43 
antibody ( TARDBP polyclonal antibody, Proteintech Group). 
The following day, after the primary antibodies were removed from the wells, 
three washes with PBS 0.1% TRITON were done, then specific secondary antibodies  
were added and they were incubated for 1 hour and 30 minutes, in the dark, at room 
temperature. 
In particular, the secondary antibodies used are an anti-mouse antibody 
conjugated to FITC (Fluor Chemicon) for recognizing the anti-SMN and an anti-rabbit 
conjugated to Cy3 (Cy3 Chemicon) for recognizing the anti-FUS and anti TDP-43. 
FITC fluorochrome excites to a wavelength of 450 nm (blue) and emits a light of 
wavelength of 532 nm (green) and Cy3 fluorochrome excites at a wavelength of 532 nm 
(green) and emits at 650 nm (red). 
Subsequently, the cover slips were placed on a glass slide using gel mount 
(Sigma), and frozen at -20 C. 
For the analysis of the experiments a confocal laser scanning microscopy 
(Olympus FV-300 equipped with argon, 488 nm and helium/neon, 543 nm, lasers) or 
Olympus IX70 fluorescence microscope were used.  
When we used the fluorescence microscope we used the Image J program to 
make overlapping images. 
Results and discussion. 
In our experiments, in HeLa cells (figure 27), SMN protein is localized  in the 
cytoplasm, in Gems and in the nucleoplasm; the FUS protein is only located in the 
nucleoplasm.  
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Figure 27: Confocal microscope image of HeLa  cells. We used anti-SMN (mouse, 1:150, BD Transduction 
Laboratories TM) and poly- FUS (rabbit, 1:200, Proteintech Group), then we used secondary anti-mouse FITC 
conjugated (1:1000) (green) and anti-rabbit Cy3 conjugated (1:2000) (red). 
 
 
In SH-SY5Y cells (figure 28) SMN and FUS proteins have the same distribution 
of HeLa cells but the Gems are less than the HeLa cells.  
 
Figure 28: Confocal microscope image of SH-SY5Y cells. We used anti-SMN (mouse, 1:150, BD Transduction 
Laboratories TM) and poly- FUS (rabbit, 1:200, Proteintech Group), then we used secondary anti-mouse FITC 
conjugated (1:1000) (green) and anti-rabbit Cy3 conjugated (1:2000) (red). 
 
 
These results were presented in a poster for SINS Congress, Rome, October 3 to 
5 (P02-116). 
Overall we show that FUS and SMN levels are higher in the nucleus in HeLa and 
neuroblastoma SH-SY5Y cells. In particular, the FUS protein is always diffusely 
expressed in the nucleoplasm in both cell lines (figure 27 and figure 28). However, the 
SMN protein in HeLa cells (figure 27) predominates in Gems but also shows a 
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detectable expression in the cytoplasm and in the nucleoplasm; in SH-SY5Y cells, Gems 
are relatively rare (figure 28). These experiments were done several times. 
Then we analyzed the TDP-43 localization and we saw that it is a nuclear and 
cytoplasmic protein.  
In one study it was found that TDP-43 protein is located in the Gems (118) but we 
found that in the HeLa cells, the TDP-43 protein is not in these sub-nuclear bodies 
(figure 29). 
 
Figure 29: Fluorescence microscopy image of HeLa cells. We used anti-SMN (mouse, 1:150, BD Transduction 
Laboratories TM) and anti-TD-P43 (rabbit, 1:200, Proteintech Group), then we used secondary anti-mouse FITC 
conjugated ( 1:1000) (green) and anti-rabbit Cy3 conjugated ( 1:2000) (red). The overlap of the images was done 
using the program Image J. 
 
 
The same result was also obtained in SH-SY5Y cells (figure 30); TDP-43 protein 
is found both in the nucleus and in the cytoplasm. 
                    
Figure 30: Fluorescence microscopy image of SH-SY5Y cells. We used anti-SMN (mouse, 1:150, BD Transduction 
Laboratories TM) and anti-TD-P43 (rabbit, 1:200, Proteintech Group), then we used secondary anti-mouse FITC 
conjugated (1:1000) (green) and anti-rabbit Cy3 conjugated (1:2000) (red). The overlap of the images was done using 
the Image J program. 
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Therefore, in both cell types SMN and TDP-43 proteins are found in the 
nucleoplasm and in the cytoplasm. The FUS protein is found only in the nucleoplasm. 
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CHAPTER4- ANALYSIS OF THE SMN PROTEIN 
INTERACTIONS IN SH-SY5Y CELLS. 
Introduction and objects. 
In immunofluorescence experiments we have seen that FUS and SMN proteins 
are in the nucleoplasm, then we decided to test their interaction. 
In 2012, this interaction was communicated by Tomohiro Yamazaki et al. (121) in 
HeLa cells so we decided to study this in neuroblastoma cells (SH-SY5Y). 
Materials and methods. 
CELL CULTURE: SH-SY5Y cells were grown as shown in chapter 2. 
SUBCELLULAR FRACTIONATION OF CELLS: as shown in chapter 2. 
SMN-IMMUNOPRECIPITATION: Cells were grown to about 80% confluency, 
then they were washed with cold D-PBS Dulbecco's Phosphate Buffered Saline 
(Euroclone) and they were mechanically detached from the plate, on ice, with an IP 
lysis buffer (20 mM TRIS HCl pH 8; 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM 
EDTA, protease inhibitors). 
The cell suspension was immediately put in gentle rotation, at 4 °C for 30 
minutes, then it was centrifuged at 12000 RPM for 20 minutes at 4 °C. The sample was 
immediately placed on ice and the supernatant was recovered, polyclonal anti-Bcl2 
(Santa Cruz Biotec, Santa Cruz, CA) was added to it and it was incubated for 1 hour, at 
4 °C, in gentle rotation.  
Subsequently, sepharose beads linked to protein G (Protein G Sepharose 4 Fast 
Flow, Amersham Pharmacia Biotec AB) were added to it and it was incubated for 30 
minutes, at 4 °C, in gentle rotation. This was done to mask non specific sites. 
Immediately, the samples were centrifuged for 10 minutes, at 12000 RPM, at 4 
°C, the supernatant was recovered and antibody anti SMN (0.4 µg / mL) was added and 
it was incubated overnight at 4 °C, in gentle rotation. 
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The next day, sepharose beads linked to protein G (Protein G Sepharose 4 Fast 
Flow, Amersham Pharmacia Biotec AB) were added to the sample and an incubation 
was done for 4 hours, at 4 °C, in gentle rotation. 
Then the samples were centrifuged for 3 minutes, at 2500 RPM, at 4 °C; the 
pellet was recovered and washed three times, using an IP buffer each time and 
centrifuged at 5000 RPM, for 5 minutes, at 4 °C.  
Once the last supernatant was removed, the sample buffer was added to samples 
and they were incubated at 95 °C, for 5 minutes and then were used for Western 
Blotting. 
SDS-PAGE AND WESTERN BLOTTING ANALYSIS: As shown in chapter 2  
but the samples were carried in polyacrylamide 15 % gel. 
For Western Blotting the primary antibodies used were: the SMN antibody 
(purified mouse Anti-SMN, BD Transduction Laboratories™) and the FUS antibody 
(FUS monoclonal antibody, Proteintech Group).  The secondary antibodies used were 
anti mouse conjugated to horseradish peroxidase. 
Results and discussion. 
To understand whether the proteins FUS and SMN interact in SH-SY5Y cells we 
did SMN-FUS co-immunoprecipitation experiments in triplicate. 
It is possible to see the result in figure 31 which shows that the two proteins 
interact and specifically the SMN protein interacts with the 68 kDa FUS isoform.  
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Figure 31: Co-immunoprecipitation SMN-FUS from SH-SY5Y cells . We used the SMN antibody (BD Transduction 
Laboratories TM) to pull down the proteins (IP). The proteins were loaded on an 15% polyacrylamide gel and 
electrophoresed. After the proteins fall down with the SMN antibody, we used the SMN antibody again for the blot in 
lane 2 and we used the FUS antibody (Proteintech Group) for the blot in lane 4. In lane 4 both bands correspond to 
different isoforms of FUS, including the smallest that could be a product of proteolysis of the intact protein, and the  
bands correspond to the IgG. The isoform of FUS (68 kDa) that interacts with SMN can also be seen. In lane 2 there 
is a specific band of SMN and there are also the bands that correspond to the IgG. In lane 1 there is SH-SY5Y total 
cells lysates and we used the SMN antibody for the blot. Conversely in the lane 3 we used the FUS antibody. 
 
These results were presented in a poster at SINS Congress, Rome, October 3 to 5 
(P02-116). 
 
From experiments on the isoforms of FUS (Chapter 2), it was shown (figure 24) 
that the 68 kDa isoform was mainly in the nucleus. In order to figure out which 
subcellular compartment the interaction SMN-FUS occurs, SH-SY5Y cells were 
fractionated and each cell fraction was studied by SMN-FUS co-immunoprecipitation. 
These experiments show that the two proteins interact ( figure 31) and they interact in 
the nucleus (figure 32). In figure 32 a FUS  band with low molecular weight appears, 
that is not present in figure 24. This could be interpreted as a FUS isoform that is 
present in case of protein cleavage, for example due to the alteration of the sample 
during processing. 
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Figure 32: In the first lane: western blot for FUS from nuclear fraction of SH-SY5Y cells; in the second lane: same 
fraction immunoprecipitated with SMN; in third lane: western blot for FUS from the cytoplasmic fraction of SH SY5Y 
cells and in fourth lane: western blot for FUS of the same fraction immunoprecipitated with SMN. The FUS antibody 
1:4000 (FUS monoclonal antibody, Proteintech Group), anti mouse 1:10000. 
 
 
The discovery of this nuclear interaction is very important because both proteins 
are involved in the pathogenesis of amyotrophic lateral sclerosis. 
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CHAPTER 5- SH-SY5Y DIFFERENTIATION AND SMN, 
FUS PROTEINS ANALYSIS. 
Introduction and objects. 
After discovering that FUS and SMN proteins are present in SH-SY5Y cells in 
different isoforms and after realizing that these proteins interact in the nucleus of these 
cells, we wanted to analyze the expression of the same proteins and their interaction 
during differentiation of neuroblastoma cells (SH-SY5Y) in human neuron-like cells. 
It was discovered that the SMN protein is located in the growth cones and it 
stimulates neurite outgrowth in cultures (122). 
Setola et al. found a particular SMN isoform, a-SMN (axonal-SMN), which is 
derived from alternative splicing. This isoform is down-regulated during early 
development in different tissues. In the spinal cord it is selectively expressed in motor 
neurons and mainly localized in axons and stimulates motor neuron axonogenesis (123). 
In one study, it was shown that the FUS expression decreases during 
differentiation of SH-SY5Y cells with retinoic acid but its localization does not change 
(124). 
In Drosophila, abnormalities in the FUS protein cause alteration of the 
neuromuscular junction (125). 
The neuroblastoma cell line, SH-SY5Y, can be induced to undergo differentiation 
in vitro by addition of retinoic acid (RA) and brain-derived neurotrophic factor ( BDNF) 
(126). 
Materials and methods. 
DIFFERENTIATION: Before plating the cells, the plates were pretreated with 
poly-ornithine (Sigma-Aldrich, 1x in boric acid) or poly-D-lysine (Sigma-Aldrich,100 
µg/ml in bi-distilled water). 
Then the SH-SY5Y cells were seeded in a multi-well plate and in a 75 cm 
2
 
Falcon flask, in Dulbecco’s modified Eagle’s medium (DMEM, Euroclone) 
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supplemented with Nutrient Mixture F-12 (1:1, GIBCO) and with 10% fetal calf serum 
(Euroclone), 2 mM L-glutamine (Euroclone), 100 U/ penicillin and 100 µg streptomycin 
(Euroclone). 
The cells were placed in an incubator for one day and the next day they were 
looked at under the light microscope.  After confirming their adherence to the plate, the 
cells were treated with retinoic acid (Sigma-Aldrich). 
We used different concentrations of retinoic acid (10 µM, 20 µM, 40 µM) but 
we saw that changing the concentration has not effect on the final result. 
We carried out several cycles of treatment with retinoic acid to test the changes 
in protein localization. About every two days the medium was changed and retinoic acid 
was added again. 
IMMUNOFLUORESCENCE: As described in Chapter 3. 
Results and discussion. 
Overall, the experiments of neuroblastoma cells differentiation into neuronal-
like cells did not show any change in the cellular distribution of the FUS and SMN 
proteins. Specifically, we had the best level of differentiation in the following treatment 
with retinoic acid for 15 days (figure 33). 
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Figure 33: Optical microscope images; in images A, B, C, SH-SY5Y cells after about 15 days of treatment with 
retinoic acid; in D SH-SY5Y undifferentiated cells. 
 
 
During the various differentiation experiments it was noted that the deficiency of 
nutrients (culture medium not changed) and the presence of a low number of cells 
stimulate differentiation. During differentiation there is also a loss of cells in the initial 
phases and then the proliferation slows down. In fact, very few cells are in the final 
stages of differentiation. We noticed that both pretreatments (poly-ornithine or poly-D-
lysine) gave the same result but pretreatment with poly-ornithine induces greater cell 
loss in the early stages. 
Overall, in the final stages of differentiation, after about 20 days, almost all cells 
have neuronal-like morphology and more than 30% of the cells are connected through 
neuronal network-like. 
The experiments were repeated many times. 
To study the differentiation, we used an antibody anti-neurofilament 200, which 
recognizes intermediate neurofilaments, that are specific components of the neurons 
cytoskeleton. They give support to the cells in both the cytoplasm and the nucleus. 
In undifferentiated SH-SY5Y cells, the FUS protein is located in the nucleoplasm 
and the SMN protein is both in the nucleoplasm and cytoplasm (view chapter 3). The 
same result is maintained in the early stages of differentiation. 
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During differentiation, the SMN protein distributes itself in the neurite growth 
cone, in perinuclear vesicles and in the axon extension (figure 34). In the figure 35 the 
SMN distribution in axon-like extensions can be seen well . 
The FUS protein remains highly concentrated in the nucleus but in the advanced 
stages of differentiation it moves into the cytoplasm and neuritis (figure 34). 
By immunofluorescence image (figure 34) we can see that FUS and SMN 
proteins perhaps interact in the nucleus. We also performed a co-immunoprecipitation 
experiment, but we do not present this figure, which showed that the two proteins 
interact. It will be a future goal to repeat this study to validate the result. 
 
 
Figure 34: Fluorescence microscope images of SH-SY5Y cells during differentiation. In the first picture, from left, 
cells exposed to antibody purified mouse Anti-SMN, BD Transduction Laboratories™( 1:150) and an anti-mouse 
antibody conjugated to FITC ( 1:1000); in the second image cells exposed to FUS polyclonal antibody, Proteintech 
Group (1:200) and an anti-rabbit antibody conjugated to Cy3 ( 1:2000); in the third image merge of the two images, 
made with image J program. 
 
 
In these experiments, we also studied the intermediate neurofilaments. They are 
found both in the cytoplasm and in the axon and they co-localize with the SMN protein 
(figure 35).  
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Figure 35: Confocal microscope image, SH-SY5Y cells partially differentiated with retinoic acid. In the first picture, 
from left, cells exposed to antibody purified mouse Anti-SMN, BD Transduction Laboratories™( 1:150) and an anti-
mouse antibody conjugated to FITC ( 1:1000), in the second image cells exposed to Neurofilament 200 antibody 
1:200 (Anti-Neurofilament 200 polyclonal antibody, Sigma-Aldrich) and an anti-rabbit antibody conjugated to Cy3 ( 
1:2000). ); in the third image merge of the two images, made with image J program. 
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CHAPTER 6- SMN AND FUS PROTEINS ANALYSIS IN 
HUMAN FIBROBLAST OF AN ASYMPTOMATIC 
SUBJECT WITH THE P525L MUTATION IN THE FUS 
GENE.  
Introduction and objects. 
FUS mutations are responsible for ~3% of familial amyotrophic lateral sclerosis 
and for < 1% of sporadic ALS (128). 
The P525L mutation was found in a Sicilian patient but also in two Japanese 
sisters who had a very aggressive and rapid disease progression (129) (130). In addition, 
the same mutation was found in a 11 year old girl with juvenile sporadic amyotrophic 
lateral sclerosis (131). So this mutation is present in both sporadic and familial ALS and 
it is characterized by a very aggressive phenotype. 
In a recent study, Sabatelli et al. showed that the FUS R521C mutation causes 
FUS cytoplasmic translocation (132). 
In another study, done by D Domann et al, it has been reported that in many 
cases of familial amyotrophic lateral sclerosis, many FUS mutations fall on its C-
terminal portion, in particular on the NLS, which is required for its correct localization. 
Furthermore, the mutations on  three arginine to alanine, which are frequently in 
familial amyotrophic lateral sclerosis (R521A, R522A, R524A) cause, in HeLa cells, 
FUS cytoplasmic mis-localization. It has also been shown that different mutations cause 
different mis-localization degrees but no mutation causes complete FUS absence from 
the nucleus and the P525L mutation has the worst effect (133) . 
The de novo mutation in FUS P525L causes ALS with juvenile onset and the 
course of the disease very accelerated (134). 
It was also discovered that expression of different FUS mutants (R521C, R521H, 
P525L) in neurons causes axonal defects, because the SMN protein is accumulated in 
FUS aggregates and therefore the level of this protein decreases in axons (135). 
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Finally, FUS mutations have an effect on snRNP localization (136). 
For all these reasons, we investigated FUS and SMN proteins in fibroblasts from 
an asymptomatic subject with P525L FUS mutation. She is the sister and daughter of the 
subjects who died of ALS. At the same time, her brother and uncle have been studied 
too because they are healthy subjects without mutations. A neurological control was 
also analyzed. 
Materials and methods. 
SKIN BIOPSY: A biopsy was taken of the subject's arm and immediately placed 
in cold D-PBS Dulbecco's Phosphate Buffered Saline (Euroclone). Subsequently 
adipose tissue was removed from biopsy and the piece was divided into several parts. 
Each of them was placed in a well of a multiwell plate, containing Dulbecco’s modified 
Eagle’s medium (DMEM, Euroclone) with 10% calf serum (Euroclone), 2 mM L-
glutamine (Euroclone) , 100 U/ penicillin and 100 µg streptomycin (Euroclone). 
The plate was placed in incubator and it was left there until the fibroblasts were 
precipitated. When that happened, the biopsy piece was removed and the fibroblasts 
were transferred into 75 cm 
2
 Falcon flask. 
CELL CULTURE: The human fibroblasts taken from skin biopsy were grown in 
75 cm 
2 Falcon flask filled in Dulbecco’s modified Eagle’s medium (DMEM, 
Euroclone) with 10%  fetal calf serum (Euroclone), 2 mM L-glutamine (Euroclone) , 
100 U/ penicillin and 100 µg streptomycin (Euroclone). 
IMMUNOFLUORESCENCE: As described in Chapter 3. The specific primary 
antibodies that we used are: The SMN antibody (purified mouse Anti-SMN, BD 
Transduction Laboratories™) and the FUS antibody (FUS polyclonal antibody, 
Proteintech Group). The secondary antibodies that we used are the anti-mouse antibody 
conjugated to FITC (Fluor Chemicon) for recognizing the anti-SMN and an the anti-
rabbit conjugated to Cy3 (Cy3 Chemicon) for recognizing the anti-FUS.  
 
60 
 
Results and discussion. 
We analyzed the distribution of FUS and SMN proteins in fibroblasts from a 
patient with a neurologic disease that does not affect the motor neurons (neurological 
control), from an asymptomatic girl with the FUS P525L mutation and from her brother 
and her uncle (healthy controls). From these studies we found that there is not 
difference between neurological and healthy controls fibroblasts but there is difference 
between these fibroblasts and those of the girl with P525L FUS mutation.  
In fact, in all analyzed fibroblasts, the FUS protein was in the nucleus, however 
in those with P525L FUS mutation the FUS protein was located in both the nucleus and 
in the cytoplasm. The distribution of SMN protein was the same in all samples. 
The result of the neurological control fibroblasts is reported in figure 36. 
 
Figure 36: Confocal microscope images of human fibroblast (neurological control). in the first picture, from left, 
cells exposed to antibody purified mouse Anti-SMN, BD Transduction Laboratories™(1:150) and an anti-mouse 
antibody conjugated to FITC (1:1000); in the second cells exposed to FUS polyclonal antibody, Proteintech Group 
(1:200) and an anti-rabbit antibody conjugated to Cy3 (1:2000); in the third image image marge of the two images. 
 
 
The same result has been obtained from the study of healthy fibroblasts but we 
do not show the images because they are the same as the neurological control. 
In particular in both healthy controls, the FUS protein is only in the nucleus in 
most of the cells analyzed. 
Conversely, in subjects with P525L mutation, the FUS protein is found both in 
the nucleus and in the cytoplasm in most of the cells analyzed (figure 37). 
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Figure 37: Confocal microscope images of human fibroblast of subjects with P525L mutation in FUS, in the first 
picture, from left, cells exposed to antibody purified mouse Anti-SMN, BD Transduction Laboratories™( 1:150) and 
an anti-mouse antibody conjugated to FITC ( 1:1000); in the second image cells exposed to FUS polyclonal antibody, 
Proteintech Group (1:200) and an anti-rabbit antibody conjugated to Cy3 ( 1:2000), the image on the right represents 
the overlap of the other two images. 
 
 
To validate these findings a statistical analysis was done through the 
construction of a 2X2 table (table 2) and the implementation of χ 2 test on it. 
Table 2 includes the data corresponding to the translocation of the FUS protein 
in the cytoplasm in healthy controls and in subject with the mutation. 
OBSERVED 1
CELLS WITH FUS IN 
NUCLEUS AND IN 
CYTOPLASM
CELLS WITH FUS ONLY IN 
NUCLEUS
MUTATION P525L FUS 88 35 123
CONTROL 1 2 111 113
90 146 236
 
Table 2: 2X2 table that includes data corresponding to the analysis of the translocation of the FUS protein in the 
cytoplasm in healthy controls than in subject with the mutation. 
 
 
The χ 2 tests done on above table returned a χ 2 value of 121,5. The synoptic 
table of χ 2 shows the critical value of 7.88 at a probability of 0.99. It can be said that, 
with a 1% probability of error, the frequency of FUS translocation is significantly 
different between the subject with the mutation than in the healthy controls. 
Subsequently, these data were reported in a histogram (figure 38), where the 
error bars represent the absolute error, calculated both for the subject with the mutation 
(red) and for the healthy controls (blue). 
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Figure 38: Table and histogram that represent the rate of cells that have FUS protein both the cytoplasm and in the 
nucleus, in subjects with P525L FUS mutation that in healthy subjects. 
 
 
In this graph (figure 38) there is not overlap between the data of the subject with 
the mutation and control subjects and then the translocation frequencies are different in 
the two samples. This histogram confirms the data. 
Simultaneously, the growth of the fibroblasts of the asymptomatic subject with 
P525L FUS mutation was analyzed. 
In particular, the cells were observed for 15 days and it was found that the 
fibroblasts with mutation P525L FUS have a limited growth period. 
During the observation, after a couple of days, some vesicles appear in the cells 
(figure 39) and from this moment on, a decrease in cell growth was noted. 
 
Figure 39: Fibroblast with P525L FUS mutation, after a couple of days from its seeding in plate; optical microscope, 
40 X. 
 
Immuno-fluorescence experiments were done on these same cells to evaluate the 
distribution of SMN and FUS proteins (figure 40). 
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Figure 40: Fluorescence microscope images of human fibroblast of subject with P525L FUS, in the first picture, 
from left, cells exposed to FUS polyclonal antibody, Proteintech Group (1:200) and an anti-rabbit antibody 
conjugated to Cy3 ( 1:2000); in the second image, cells exposed to antibody purified mouse Anti-SMN, BD 
Transduction Laboratories™( 1:150) and an anti-mouse antibody conjugated to FITC ( 1:1000). 
 
 
Even in these mutated cells, such as those analyzed previously, FUS and SMN 
proteins are found both in the nucleus and in the cytoplasm. This demonstrates that their 
distribution does not change during cell growth. 
The two proteins are not in the vesicles but some granules are labeled with both 
anti-SMN and anti-FUS antibodies. 
Therefore, these studies have shown, for the first time, that in case of the P525L 
FUS mutation, even if the subject does not manifest the disease, changes begin in the 
cells and specifically the FUS protein translocates to the cytoplasm, assuming a 
different location compared to controls, however the distribution of the SMN protein 
remains unchanged. 
Even if there is a mis-localization of the FUS protein in fibroblasts, yet there is 
not a manifestation of amyotrophic lateral sclerosis, then in the future, monitoring 
studies of the FUS protein in this subject will be done. 
In addition, we will study the specific isoforms involved in this translocation and 
the FUS/SMN interaction, to see if there are any changes due to mutation in FUS or its 
mis-localization. 
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FINALLY CONCLUSIONS. 
The amyotrophic lateral sclerosis (ALS) pathogenesis is not yet completely 
clear. So the PhD research aim was to provide a further contribution to the knowledge 
on the ALS molecular basis, with particular attention to the role of SMN. 
Specifically, we studied the SMN gene with RFLP-PCR and all our experiments 
produced the same results:  
 from analysis of SMN exon 7: in each positive control (SMA patient) a 
single band always appeared (176 bp), corresponding to the SMN2 gene, 
however in each neurological control and in ALS patients two bands 
always appeared and they corresponded to the SMN1 (188 bp) and SMN2 
(176 bp) genes; 
 from analysis of SMN exon 8: in the positive control (SMA patient) two 
bands always appeared (122 bp and 78 bp), which corresponded to the 
SMN2 gene, however in the neurological controls and in ALS patients, 
there are always three bands (200 bp; 122 bp and 78 bp) , which 
correspond to the SMN1 and SMN2 genes. 
 
These data indicate that, contrary to what happens in spinal muscle atrophy 
(SMA), the deletion of the SMN1 gene is not involved in the pathogenesis of ALS. 
These data gives a further contribution to the understanding of the molecular basis of 
the disease studied.  In fact, there are still conflicting ideas about the role of the SMN 
gene. 
In the future, it would interesting to see if the number of the copies of SMN 
genes varies or if there are variations in their promoter that could alter the transcription.  
We also analyzed the role of SMN in the pathogenesis of ALS at the protein 
level. In particular we studied the SMN protein isoforms to understand whether specific 
isoforms are involved in the ALS pathogenesis. We also analyzed the isoforms of the 
FUS and TDP-43 proteins. These are involved in ALS and they are SMN potential 
interactors.  
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From these studies we confirm that different SMN isoforms are in the various 
cell types analyzed. In fact, in human leukocytes, the SMN protein is present in various 
isoforms of 40 kDa, 30 kD, 20 kDa and 15 kDa. A 44 kDa isoform is only present in 
HeLa cells. the 45 kDa SMN isoform is the most expressed in SH-SY5Y cells.  
In addition, we show that different SMN isoforms are in the various cell 
compartments, especially between the nucleus and the cytoplasm of human leukocytes. 
In particular we noted that in the cytoplasm the smaller isoform is absent and the larger 
one seems to be less expressed.   
Between the two cell compartments of the HeLa and SH-SY5Y cells there is only 
a difference of expression level, in fact the SMN seems to be more expressed in the 
nuclei. It also seems that, in the ALS samples, the 40 kDa isoform of SMN is lost but 
these data need to be confirmed. 
We have also analyzed the TDP-43 expression in human leukocytes and 
neuroblastoma cells (SH-SY5Y). Multiple TDP-43 isoforms are in leukocytes of 
neurological controls and the isoform with higher molecular weight is found only in the 
nucleus. However, the experiment in ALS leukocytes showed an opposite result to that 
obtained from control subjects. In fact, only the 43 kDa TDP- 43 isoform is found in 
nucleus of these cells and there is a smaller amount of this protein. Therefore, if these 
data can be replicated, we can say that TDP-43 translocates to the cytoplasm even when 
it is not mutated and that this translocation may initiate or contribute to the pathogenic 
process. 
Even multiple isoforms of the protein TDP-43 are in neuroblastoma cells and the 
43 kDa TDP- 43 isoform is the most expressed both in the nucleus and in the cytoplasm. 
In conclusion, we studied the FUS expression in human leukocytes, in 
neuroblastoma (SH-SY5Y) and in HeLa cells. In human leukocytes the FUS protein is 
present in different isoforms. In particular a 68 kDa specific isoform is present in the 
nucleus. However there is not difference between control and ALS patients analyzed. 
The same results were found in HeLa and in SH-SY5Y cells.  
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Therefore, the three proteins studied, SMN, TDP-43 and FUS, have various 
isoforms that are often found in different cellular compartments. 
Then, in the future, the meaning of these isoforms will be studied. Experiments 
on ALS leukocytes will be also repeated several times to understand whether there is a 
difference in the expression of isoforms between controls and diseased patients and if 
this difference may contribute to the pathogenesis of ALS . 
After studying SMN, TDP-43 and FUS protein isoforms and after seeing that 
they often have a different distribution in the cells, the analysis was continued by 
immunofluorescence.  
This investigation was done to study if any changes in the proteins distribution 
are present in different cell types or in the case of particular conditions, such as 
differentiation or mutation.  
In our experiments, the SMN protein is localized in the cytoplasm, in Gems and 
in the nucleoplasm in HeLa cells. Conversely, the FUS protein is only found in the 
nucleoplasm. In SH-SY5Y cells SMN and FUS proteins have the same distribution of 
HeLa cells  but Gems less are than HeLa cells. 
After we saw that both the FUS and the SMN proteins are in the nucleoplasm we 
decided to test their interaction in SH-SY5Y cells. These cells were fractionated and each 
cell fraction was studied by SMN-FUS co-immunoprecipitation. These experiments 
show that the two proteins interact in the nucleus and specifically the SMN protein 
interacts with the 68 kDa FUS isoform. This is an important finding because both 
proteins are involved in ALS. 
Later, we analyzed the expression of the same proteins and their interaction 
during differentiation of neuroblastoma cells (SH-SY5Y) in human neuron-like cells. 
Overall, these experiments showed that there is not change in the cellular distribution of 
the FUS and SMN proteins during differentation. It has also been shown that the 
intermediate neurofilaments co-localize with the SMN protein. As a final analysis, we 
evaluated the distribution of FUS and SMN proteins when FUS gene is mutated.  
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Specifically, we investigated this in fibroblasts from an asymptomatic subject 
with the P525L FUS mutation. She is the sister and daughter of subjects who died of 
ALS.  
At the same time, her brother and her uncle have been studied too, they are 
healthy subjects without mutations. A neurological control was also analyzed.  
In all the fibroblasts analyzed, the FUS protein was in the nucleus however in 
those with P525L mutation, the FUS protein was located in both the nucleus and in the 
cytoplasm. The distribution of SMN protein was the same in all samples. 
Simultaneously with these studies the growth of the fibroblasts was also analyzed. 
 From these studies we discovered that the fibroblasts with mutated FUS have a 
limited growth period when compared to controls. In fact, after a couple of days, some 
vesicles appear in the cells and from this moment on, a noted decrease in cell growth 
occurred.  
We will do another study to better understand this process and to have more 
information on the topic. 
Consequently, from my PhD research we discerned that SMN is not involved in 
the pathogenesis of amyotrophic lateral sclerosis at the genetic level. It does however 
seem to be involved at the protein level because we observed that in the leukocytes of a 
patient with ALS the 40-kDa isoform of SMN is missing, but this remains to be 
confirmed. Furthermore, we found that in neuroblastoma cells SMN interacts with 
another protein involved in ALS, FUS, and specifically interacts with the 68 kDa FUS 
isoform in the nucleus.  
Finally, for the first time we show that an asymptomatic subject with the P525L 
mutation in the  FUS gene has changes in the cellular distribution of the FUS protein 
even before ALS manifests itself. 
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